NeoGenomics financials
$18.74−2.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.7M | $186.7M | $190.2M | $187.8M | $181.3M | $168.0M | $172.0M | $167.8M | $164.5M | $156.2M | $155.6M | $152.0M |
| Gross profit | $91.9M | $80.9M | $83.3M | $80.4M | $77.3M | $73.2M | $77.3M | $74.9M | $72.5M | $65.5M | $67.6M | $62.3M |
| Gross margin | 45.6% | 43.3% | 43.8% | 42.8% | 42.6% | 43.6% | 44.9% | 44.6% | 44.1% | 41.9% | 43.5% | 41.0% |
| Operating income | -$9.8M | -$18.2M | -$13.4M | -$27.0M | -$47.6M | -$27.8M | -$18.4M | -$21.2M | -$21.9M | -$30.6M | -$18.6M | -$24.2M |
| Net income | $2.2M | -$17.1M | -$9.9M | -$27.1M | -$45.1M | -$25.9M | -$15.3M | -$17.7M | -$18.6M | -$27.1M | -$14.3M | -$18.5M |
| Net margin | 1.1% | −9.2% | −5.2% | −14.4% | −24.9% | −15.4% | −8.9% | −10.5% | −11.3% | −17.3% | −9.2% | −12.2% |
| Diluted EPS | $0.02 | $-0.13 | $-0.08 | $-0.21 | $-0.35 | $-0.20 | $-0.12 | $-0.14 | $-0.15 | $-0.21 | $-0.11 | $-0.15 |
| EBITDA | $6.4M | -$1.8M | $3.6M | -$3.5M | -$10.3M | -$10.1M | $1.5M | -$2.2M | -$2.3M | -$9.9M | -$17.4M | -$3.9M |
| Operating cash flow | $20.0M | -$8.1M | $1.3M | $8.9M | $20.3M | -$25.3M | $9.8M | $9.2M | $13.9M | -$25.9M | $17.8M | -$5.5M |
| Free cash flow | $11.7M | -$13.1M | -$6.5M | $570.0K | $14.0M | -$29.8M | -$1.8M | -$1.6M | $814.0K | -$31.5M | $10.7M | -$9.8M |
| Diluted shares | 130.8M | 129.2M | 128.7M | 128.4M | 127.9M | 127.4M | 127.2M | 127.0M | 126.4M | 126.1M | 125.9M | 125.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $145.5M | $146.1M | $159.6M | $164.1M | $154.7M | $346.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $9.0M | $11.9M |
| Total debt | $380.0M | $342.2M | $341.9M | $341.5M | $341.1M | $541.8M |
| Total assets | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B |
| Total liabilities | $566.5M | $517.8M | $523.3M | $536.5M | $539.9M | $713.2M |
| Shareholders' equity | $785.7M | $828.8M | $836.6M | $838.3M | $854.0M | $888.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology